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Definition  
• (Congestive) heart failure (HF) is a clinical syndrome caused by 
a structural and/or functional cardiac abnormality, resulting in 
a reduced cardiac output and/or elevated intracardiac 
pressures at rest or during stress, characterized by typical 
symptoms (e.g. breathlessness, ankle swelling and fatigue) 
that may be accompanied by signs (e.g. elevated jugular 
venous pressure, pulmonary crackles and peripheral oedema). 
• Before clinical symptoms become apparent, patients can 
present with asymptomatic structural or functional cardiac 
abnormalities (asymptomatic systolic  left ventricle (LV) 
dysfunction), which recognition  as precursors of HF is 
important  for starting its treatment as soon as possible in deal 
to reduce patients mortality. 
eurheartj.oxfordjournals.org/content/early/2016/06/08/eurheartj.ehw128 
Epidemiology   
(Hear Failure around the World) 
eurheartj.oxfordjournals.org/content/early/2016/06/08/eurheartj.ehw128 
• The prevalence of HF depends on the definition applied, but is 
approximately 1–2% of the adult population in developed 
countries, rising to ≥10% among people >70 years of age. 
• Among people >65 years of age presenting to primary care 
with breathlessness on exertion, one in six will have 
unrecognized HF (mainly HFpEF). 
• The lifetime risk of HF at age 55 years is 33% for men and 28% 
for women. 
• The proportion of patients with HFpEF ranges from 22 to 73%, 
depending on the definition applied, the clinical setting 
(primary care, hospital clinic, hospital admission), age and sex 
of the population, previous myocardial infarction and the year 
of publication. 
Epidemiology   
(The Heart Failure Epidemic) 
medicographia.com/2012/02/the-heart-failure-epidemic/ 
The relative proportion of cases with (grey bars) and without 
(red bars) preserved LV systolic function. 
Risk Factors and Etiology 
(Underlying Causes of Systolic Heart Failure) 
• Coronary artery disease 
• Diabetes mellitus 
• Hypertension 
• Valvular heart disease 
(stenosis or regurgitant 
lesions) 
• Arrhythmia 
(supraventricular or 
ventricular) 
• Infections and inflammation 
(myocarditis) 
• Peripartum cardiomyopathy 
• Congenital heart disease 
• Drugs (either recreational, 
such as alcohol and cocaine, 
or therapeutic drugs with 
cardiac side effects, such as 
doxorubicin) 
• Idiopathic cardiomyopathy 
• Rare conditions (endocrine 
abnormalities, 
rheumatologic disease, 
neuromuscular conditions) 
 
emedicine.medscape.com/article/163062-overview#a4 
Risk Factors and Etiology 
(Underlying Causes of Diastolic Heart Failure) 
• Coronary artery disease 
• Diabetes mellitus 
• Hypertension 
• Valvular heart disease   
• Hypertrophic 
cardiomyopathy 
• Restrictive 
cardiomyopathy   
• Constrictive pericarditis 
medscape.org/viewarticle/491741_3 
Risk Factors and Etiology 
(Underlying Causes of Acute Heart Failure) 
• Acute valvular 
regurgitation 
• Myocardial infarction 
• Myocarditis 
• Arrhythmia 
• Drugs (e.g., cocaine, 
calcium channel 
blockers, or beta-blocker 
overdose) 
• Sepsis 
nature.com/nrcardio/journal/v9/n8/fig_tab/nrcardio.2012.60_F1.html 
Risk Factors and Etiology 
(Underlying Causes of  High-Output Heart Failure) 
• Anemia 
• Systemic arteriovenous 
fistulas 
• Hyperthyroidism 
• Beriberi heart disease 
• Paget disease of bone 
• Fibrous dysplasia 
• Multiple myeloma 
• Pregnancy 
• Glomerulonephritis 
• Polycythemia vera 
• Carcinoid syndrome 
emedicine.medscape.com/article/163062-overview#a4 content.onlinejacc.org/article.aspx?articleid=1139115 
Risk Factors and Etiology 
(Underlying Causes of Right  Heart Failure) 
• Left ventricular failure 
• Coronary artery disease 
(ischemia) 
• Pulmonary hypertension 
• Pulmonary valve stenosis 
• Pulmonary embolism 
• Chronic pulmonary 
disease 
• Neuromuscular disease 
emedicine.medscape.com/article/163062-overview#a4 fairviewebenezer.org/HealthLibrary/Article/115854EN 
Risk Factors and Etiology 
(Fundamental Causes of Heart Failure) 
Fundamental causes 
include the biological 
mechanisms, through 
which either an increased 
hemodynamic burden or a 
reduction in oxygen 
delivery to the 
myocardium results in 
impairment of myocardial 
contraction. 
emedicine.medscape.com/article/163062-overview#a4 .scielo.br/scielo.php?pid=S0066-782X2014000500013&script=sci_arttext&tlng=en 
Risk Factors and Etiology 
(Precipitating Causes of Heart Failure) 
Overt heart failure may be 
precipitated by progression 
of the underlying heart 
disease (e.g., further 
narrowing of a stenotic aortic 
valve or mitral valve) or 
various conditions (fever, 
anemia, infection) or 
medications (chemotherapy, 
NSAIDs) that alter the 
homeostasis of heart failure 
patients. 
emedicine.medscape.com/article/163062-overview#a4 eurheartj.oxfordjournals.org/content/early/2015/09/28/eurheartj.ehv513 
Risk Factors and Etiology 
(Genetic Causes of Heart Failure) 
• Dilated 
cardiomyopathy. 
• Arrhythmic 
cardiomyopathy. 
• Right ventricular 
cardiomyopathy . 
• Restrictive 
cardiomyopathy. 
emedicine.medscape.com/article/163062-overview#a4 /circ.ahajournals.org/content/101/21/2490.figures-only 
Idiopathic Restrictive Cardiomyopathy, 
marked interstitial fibrosis 
Mechanisms   
(The Common Pathophysiologic State)     
 en.wikipedia.org/wiki/Heart_failure#Causes http://emedicine.medscape.com/article/163062-overview#a3 
• The heart in HF may have a reduced force of contraction due to 
overloading of the ventricle with fails the Frank–Starling law. 
• A reduced stroke volume (SV) may occur as a result of a failure 
of systole, diastole or both, that contributes to the exercise 
intolerance commonly seen in HF. 
• A common finding in HF is an increased sympathetic  and  
renin-angiotensin-aldosterone system (RAAS) activity with 
other neurohumoral adjustments that leads to salt and water 
retention, resulting in deep disturbances of heart function and 
structure with enlargement of the ventricles and their 
remodeling.  
• This increases the risk of cardiac arrest (specifically due to 
abnormal ventricular heart rhythms), and reduces blood supply 
to the rest of the body.    
 
Mechanisms   
(Myocytes and Myocardial Remodeling)     
 emedicine.medscape.com/article/163062-overview#a3 
• In the HF, increased myocardial volume is characterized by 
larger myocytes approaching the end of their life cycle and  as 
more myocytes drop out, an increased load is placed on the 
remaining myocardium, and this unfavorable environment is 
transmitted to the progenitor cells responsible for replacing 
lost myocytes. 
• Progenitor cells become progressively less effective as the 
underlying pathologic process worsens and myocardial failure 
accelerates.  
• This results in cellular proliferation, adverse myocardial 
remodeling, and antinatriuresis, with total body fluid excess 
and worsening of heart failure symptoms. 
Mechanisms   
(Left Ventricle Stiffness)     
 emedicine.medscape.com/article/163062-overview#a3 
• An increase in LV stiffness occurs secondary to any one of, or any 
combination of, the following 3 mechanisms:  
• rise in filling pressure,  
• shift to a steeper ventricular pressure-volume curve,  
• decrease in ventricular distensibility. 
• A shift to a steeper ventricular pressure-volume curve results, 
most commonly, not only from increased ventricular mass and 
wall thickness but also from infiltrative, endomyocardial fibrosis, 
and myocardial ischemia. 
• Parallel upward displacement of the diastolic pressure-volume 
curve is generally referred a decrease in ventricular distensibility 
that caused by extrinsic compression of the ventricles. 
Mechanisms   
(Concentric Left Ventricle Hypertrophy)     
 emedicine.medscape.com/article/163062-overview#a3 
• Pressure overload that leads to concentric LV hypertrophy 
(LVH), shifts the diastolic pressure-volume curve to the left 
along its volume axis and ventricular diastolic pressure is 
abnormally elevated, although chamber stiffness may or may 
not be altered. 
• Increases in diastolic pressure lead to increased myocardial 
energy expenditure, remodeling of the ventricle, increased 
myocardial oxygen demand, myocardial ischemia, and 
eventual progression of the maladaptive mechanisms of the 
heart that lead to decompensated HF. 
Mechanisms   
(Systolic dysfunction)     
 en.wikipedia.org/wiki/Heart_failure#Causes 
• HF caused by systolic dysfunction is characterized by a 
decreased ejection fraction (less than 45%).  
• The strength of ventricular contraction is attenuated and 
inadequate for creating an adequate stroke volume, resulting 
in inadequate cardiac output.  
• Because the ventricle is inadequately emptied, ventricular end-
diastolic pressure and volumes increase and this is transmitted 
to the atrium.  
• On the left side of the heart it causing pulmonary edema and 
on the right side of the heart it resulting in 
dependent peripheral edema. 
Mechanisms   
(Diastolic dysfunction)     
 en.wikipedia.org/wiki/Heart_failure#Causes 
• HF caused by diastolic dysfunction is generally described as the 
backward failure of the ventricle to adequately relax and 
typically denotes a stiffer ventricular wall with inadequate 
filling of the ventricle, and therefore inadequate SV.  
• Diastolic dysfunction can be caused by processes similar to 
those that cause systolic dysfunction, particularly causes that 
affect cardiac remodeling. 
• The patient may be completely asymptomatic at rest, but is 
exquisitely sensitive to increases in heart rate, and sudden 
bouts of tachycardia  may result in flash pulmonary edema.   
Mechanisms   
(Arrhythmias)     
 emedicine.medscape.com/article/163062-overview#a3 
• Arrhythmia imparts a significant burden in all forms of HF.  
• The most significant of all rhythms associated with HF are the 
life-threatening ventricular arrhythmias.  
• Structural substrates for ventricular arrhythmias regardless of 
the underlying cause, include ventricular dilatation, 
myocardial hypertrophy, and myocardial fibrosis. 
• At the cellular level, myocytes may be exposed to increased 
stretch, wall tension, catecholamines, ischemia, and 
electrolyte imbalance.  
• The combination of these factors contributes to an increased 
incidence of arrhythmogenic sudden cardiac death in 
patients with heart failure. 
Mechanisms   
(Pressure–Volume Loops in Heart Failure )     
• Pressure–volume loop (PVL)characteristics 
in HF with preserved (black) ejection 
fraction (EF)and HF with reduced (red)  EF 
in baseline conditions (A), and in response 
to vasodilators (B).  
• (A) Curved arrow depicts the steeper end-
systolic pressure–volume relationship in HF 
with preserved EF compared with HF with 
reduced EF.  
• (B) PVL before (solid) and after (dotted) 
administration of vasodilators.  
• Arrows contrast the drop in blood pressure 
and changes in stroke volume between HF 
with preserved EF and HF with reduced EF 
in response to vasodilators. 
eurheartj.oxfordjournals.org/content/35/16/1022 
Mechanisms   
(HF affects the Systems involved in the Physiological Response)     
• Severely compromised 
cardiac function is a primary 
pathophysiological 
component in HF. 
• Patients with HF frequently 
present reduced capillary 
density and intrinsic skeletal 
muscle abnormalities, 
primarily in the form of 
diminished aerobic 
(mitochondrial) function. 
.scielo.br/scielo.php?script=sci_arttext&pid=S1413-35552008000200002 
Classification 
(International Classification of Diseases (ICD)) 
icd10coded.com/cm/ch9/I20-I25/ 
Chapter IX 
Other forms of heart disease 
(I30-I52) 
 150 Heart failure 
          I50.0 Congestive heart failure (congestive heart  
                   disease, right ventricular failure (secondary to left 
       heart failure)) 
         I50.1Left ventricular failure (cardiac asthma, left heart  
       failure, oedema of lung, pulmonary oedema) 
          I50.9 Heart failure, unspecified (cardiac, heart or  
       myocardial failure Not Otherwise Specified  
       (NOS)) 
Classification 
(New York Heart Association Functional Classification) 
en.wikipedia.org/wiki/New_York_Heart_Association_Functional_Classification 
NYHA Class Symptoms 
I 
Cardiac disease, but no symptoms and no limitation in 
ordinary physical activity, e.g. no shortness of breath 
when walking, climbing stairs etc. 
II 
Mild symptoms (mild shortness of breath and/or angina) 
and slight limitation during ordinary activity. 
III 
Marked limitation in activity due to symptoms, even 
during less-than-ordinary activity, e.g. walking short 
distances (20–100 m). 
Comfortable only at rest. 
IV 
Severe limitations. Experiences symptoms even while at 
rest. Mostly bedbound patients. 
Classification 
(Stages of Heart Failure) 
heartfailurecenter.com/hfcheartfailurestages.shtm 
HF Stages Symptoms 
A 
No objective evidence of cardiovascular disease. No 
symptoms and no limitation in ordinary physical activity. 
B 
Objective evidence of minimal cardiovascular disease. Mild 
symptoms and slight limitation during ordinary activity. 
Comfortable at rest. 
C 
Objective evidence of moderately severe cardiovascular 
disease. Marked limitation in activity due to symptoms, even 
during less-than-ordinary activity. Comfortable only at rest. 
D 
Objective evidence of severe cardiovascular disease. Severe 
limitations. Experiences symptoms even while at rest. 
Classification 
( Killip classification for  Acute Myocardial Infarction) 
heartfailurecenter.com/hfcheartfailurestages.shtm 
Killip Class Symptoms 
I 
Individuals with no clinical signs of heart failure (mortality 
6%). 
II 
 Individuals with rales or crackles in the lungs, an S3, and 
elevated jugular venous pressure (mortality 17%). 
III 
Individuals with frank acute pulmonary edema (mortality 
38%). 
IV 
Individuals in cardiogenic shock or hypotension, and 
evidence of peripheral vasoconstriction (mortality 67%). 
Clinical Investigation  
(Signs and Symptoms) 
• Exertional dyspnea 
and/or dyspnea at rest. 
• Orthopnea. 
• Acute pulmonary 
edema. 
• Chest pain/pressure 
and palpitations. 
• Tachycardia. 
• Fatigue and weakness. 
• Nocturia and oliguria. 
• Anorexia, weight loss, 
nausea. 
• Exophthalmos and/or visible 
pulsation of eyes. 
• Distention of neck veins. 
• Weak, rapid, and thready pulse. 
• Rales, wheezing. 
• S 3 gallop and/or pulsus alternans 
• Increased intensity of P 2 heart 
sound. 
• Hepatojugular reflux. 
• Ascites, hepatomegaly, and/or 
anasarca. 
• Central or peripheral cyanosis, pallor. 
 
en.wikipedia.org/wiki/Acute_coronary_syndrome#Signs_and_symptoms 
Clinical Investigation  
(Price of Signs and Symptoms) 
• Symptoms are often non-specific 
and do not help discriminate 
between HF and other problems. 
• Symptoms due to fluid retention 
may resolve quickly with diuretic 
therapy.  
• Signs, such as elevated jugular 
venous pressure and displacement 
of the apical impulse, may be more 
specific, but are harder to detect 
and have poor reproducibility. 
• Etc. 
en.wikipedia.org/wiki/Acute_coronary_syndrome#Signs_and_symptoms  
Clinical Investigation  
(Clinical Portrait of Congestive HF) 
medical-dictionary.thefreedictionary.com/heart+failure 
Diagnosis 
(Diagnostic algorithm of Non-Acute HF) 
  • Diagnostic algorithm 
for a diagnosis of HF 
of non-acute onset 
• BNP - B-type 
natriuretic peptide; 
CAD - coronary artery 
disease; MI - 
myocardial infarction; 
NT-proBNP - N-
terminal pro-B type 
natriuretic peptide.  
  eurheartj.oxfordjournals.org/content/early/2016/06/08/eurheartj.ehw128 
Diagnosis 
(The Framingham Criteria for the diagnosis of HF) 
Major criteria  
• Paroxysmal nocturnal dyspnea 
• Weight loss of 4.5 kg in 5 days in response to 
treatment 
• Neck vein distention 
• Rales 
• Acute pulmonary edema 
• Hepatojugular reflux 
• S 3 gallop 
• Central venous pressure greater than 16 cm water 
• Circulation time of 25 seconds 
• Radiographic cardiomegaly 
• Pulmonary edema, visceral congestion 
Minor criteria  
• Nocturnal cough 
• Dyspnea on 
ordinary exertion 
• A decrease in 
vital capacity by 
one third the 
maximal value 
recorded 
• Pleural effusion 
• Tachycardia (rate 
of 120 bpm) 
• Bilateral ankle 
edema 
 emedicine.medscape.com/article/155919-treatment#d5 
Diagnosis 
(The Initial Evaluation for Suspected Heart Failure) 
• Complete blood count (CBC) 
• Urinalysis 
• Electrolyte levels 
• Renal and liver function 
studies 
• Fasting blood glucose levels 
• Lipid profile 
• Thyroid stimulating 
hormone (TSH) levels 
• B-type natriuretic peptide 
levels 
 
• N-terminal pro-B-type 
natriuretic peptide 
• Electrocardiography 
• Chest radiography 
• 2-dimensional (2-D) 
echocardiography 
• Nuclear imaging  
• Maximal exercise testing 
• Pulse oximetry or arterial 
blood gas 
 
 emedicine.medscape.com/article/155919-treatment#d5 
Diagnosis 
(Natriuretic Peptide Cutoff Values for Acute decompensated HF) 
  
dovepress.com/cardiopulmonary-laboratory-biomarkers-in-the-evaluation-of-acute-dyspn-peer-reviewed-fulltext-article-OAEM 
ACEP -American College of Emergency Physicians, CKD – chronic kidney 
disease, BMI  - body mass index  
Diagnosis 
(Electrocardiography) 
  
ucsf.edu/news/2013/04/105041/routine-ekg-finding-could-signal-serious-heart-problem 
• The top ECG shows a 
reading of a person with a 
healthy heart.  
• The bottom ECG shows a 
reading of a person 
with left anterior 
fascicular block (LAFB), 
previously thought to be 
benign but found to 
potentially signal a serious 
HF. 
Diagnosis 
(Chest Radiography) 
  
Chest X-Ray signs of HF 
radiologyassistant.nl/en/p4c132f36513d4/chest-x-ray-heart-failure.html 
Views of the upper lobe vessels of a 
patient in good condition (left) and during 
a period of CHF (right). Notice also the 
increased width of the vascular pedicle 
(red arrows). 
Diagnosis 
(Transthoracic Echocardiography ) 
  
elsevier.es/en-revista-revista-portuguesa-cardiologia-english-edition--434-articulo-systemic-sclerosis-a-rare-cause-90443802 
Mild LV dilation (end-diastolic diameter 55 mm, end-systolic diameter 
49 mm), normal LV thickness, asynchronous LV wall motion, LV ejection 
fraction, LV diastolic dysfunction (restrictive pattern), right ventricular 
(RV) dilation and impaired RV systolic function (tricuspid annular plane 
systolic excursion 9 mm), without evidence of significant pulmonary 
hypertension.  
Treatment 
(General Principles) 
• The goals of treatment in patients with HF are to improve 
their clinical status, functional capacity and quality of life, 
prevent hospital admission and reduce mortality.  
• Treatment include lifestyle and pharmacological modalities 
with occasionally various forms of device therapy and rarely 
cardiac transplantation. 
• In acute decompensated HF, the immediate goal is to re-
establish adequate perfusion and oxygen delivery to end 
organs, that involve some combination of vasodilators, 
diuretic, and possibly non invasive positive pressure 
ventilation (NIPPV).  
en.wikipedia.org/wiki/Heart_failure#Management eurheartj.oxfordjournals.org/content/early/2016/06/08/eurheartj.ehw128 
Treatment 
(Lifestyle modification) 
• Behavioral modification is a primary consideration in any 
chronic HF management program, with dietary guidelines 
regarding fluid and salt intake being of particular importance. 
• Exercise should be encouraged and tailored to suit individual 
capabilities: the inclusion of regular physical conditioning as 
part of a cardiac rehabilitation program can significantly 
improve quality of life and reduce the risk of hospital 
admission for worsening symptoms however there is no 
evidence for a reduction in mortality rates as a result of 
exercise.  
• Home visits and regular monitoring at HF clinics reduce the 
need for hospitalization and improve life expectancy. 
en.wikipedia.org/wiki/Heart_failure#Management 
Treatment 
(Pharmacological Modalities: 1) 
• First-line therapy due to reduced systolic function should 
include angiotensin-converting enzyme (ACE) inhibitors (ACE-
I) or angiotensin receptor blockers (ARBs), and beta-
adrenergic blocking agents (beta blockers).  
• In people who are intolerant of ACE-I and ARBs or who have 
significant kidney dysfunction, the use of combined 
hydralazine and a long-acting nitrate; it is especially beneficial 
in African-Americans. 
• In patients with markedly reduced ejection fraction in 
addition to beta blockers and ACE-I, should be used of an 
aldosterone antagonist.  
en.wikipedia.org/wiki/Heart_failure#Management 
Treatment 
(Pharmacological Modalities: 2) 
• Second-line drug HF digitalis do not confer a mortality 
benefit.  
• Diuretics have been a mainstay of treatment for patients with 
fluid accumulation, and include diuretics classes such as loop 
diuretics, thiazide-like diuretic, and potassium-sparing 
diuretic.  
• A new therapeutic class of agents: angiotensin receptor 
neprilysin inhibitor (ARNI),   If-channel inhibitor (ivabradin. 
•  Treating  with parenteral iron if anemia is found.  
en.wikipedia.org/wiki/Heart_failure#Management 
Treatment 
(Algorithm for a Patient with Symptomatic HF and reduced EF) 
eurheartj.oxfordjournals.org/content/early/2016/06/08/eurheartj.ehw128 
Treatment 
(Angiotensin-Converting Enzyme Inhibitors) 
• ACE-I have been shown to reduce mortality and morbidity in 
patients and are recommended unless contraindicated or not 
tolerated in all symptomatic patients.  
• ACE-I should be up-titrated to the maximum tolerated dose in 
order to achieve adequate inhibition of  RAAS. 
•  There is evidence that in clinical practice the majority of 
patients receive suboptimal doses of ACE-I. 
• ACE-I are also recommended in patients with asymptomatic 
LV systolic dysfunction to reduce the risk of HF development, 
HF hospitalization and death. 
eurheartj.oxfordjournals.org/content/early/2016/06/08/eurheartj.ehw128 
Treatment 
(Angiotensin II type I receptor blockers) 
• ARBs are recommended only as an alternative in patients 
intolerant of an ACE-Is. 
• The combination of ACEI/ARBs for HF was reviewed by the 
European Medical Association, which suggested that benefits 
are thought to outweigh risks only in a select group of patients 
in whom other treatments are unsuitable.   
eurheartj.oxfordjournals.org/content/early/2016/06/08/eurheartj.ehw128 
Treatment 
(Beta-Blockers) 
• There is consensus that beta-blockers and ACE-I are 
complementary, and can be started together as soon as the 
diagnosis of HF with reduce EF is made.  
• Beta-blockers should be initiated in clinically stable patients at a 
low dose and gradually up-titrated to the maximum tolerated 
dose.  
• Beta-blockers should be considered for rate control in patients 
with HF and AF, especially in those with high heart rate. 
• Beta-blockers are recommended in patients with a history of 
myocardial infarction and asymptomatic LV systolic dysfunction 
to reduce the risk of death 
eurheartj.oxfordjournals.org/content/early/2016/06/08/eurheartj.ehw128 
Treatment 
(Mineralocorticoid/Aldosterone Receptor Antagonists) 
• Mineralocorticoid/aldosterone receptor antagonists 
(spironolactone and eplerenone) block receptors that bind 
aldosterone and, with different degrees of affinity, other steroid 
hormone (e.g. corticosteroids, androgens) receptors.  
• Spironolactone or eplerenone are recommended in all 
symptomatic patients (despite treatment with an ACE-I and a 
beta-blocker) with HF and LVEF ≤35%, to reduce mortality and HF 
hospitalization. 
• Regular checks of serum potassium levels and renal function 
should be performed according to clinical status. 
eurheartj.oxfordjournals.org/content/early/2016/06/08/eurheartj.ehw128 
Treatment 
(Diuretics) 
• Diuretics are recommended to reduce the signs and symptoms 
of congestion in patients with HF. 
• Loop diuretics produce a more intense and shorter diuresis than 
thiazides, although they act synergistically and the combination 
may be used to treat resistant oedema.  
• The aim of diuretic therapy is to achieve and maintain 
euvolemia with the lowest achievable dose.  
• The dose of the diuretic must be adjusted according to the 
individual needs over time.  
• Patients can be trained to self-adjust their diuretic dose based 
on monitoring of symptoms/signs of congestion and daily 
weight measurements. 
eurheartj.oxfordjournals.org/content/early/2016/06/08/eurheartj.ehw128 
Treatment 
(Angiotensin Receptor Neprilysin Inhibitor) 
•  Angiotensin receptor neprilysin inhibitor (ARNI) is a  new class 
of agents acting on the RAAS and the neutral endopeptidase. 
• The first in class is LCZ696, which is a molecule that combines 
the moieties of valsartan and sacubitril (neprilysin inhibitor) in a 
single substance.  
• Neprilysin inhibiting enhancing diuresis, natriuresis and 
myocardial relaxation and anti-remodelling.  
eurheartj.oxfordjournals.org/content/early/2016/06/08/eurheartj.ehw128 
Treatment 
(If-channel inhibitor) 
• Ivabradine slows the heart rate 
through inhibition of 
the If channel in the sinus node 
and therefore should only be 
used for patients in sinus 
rhythm.  
• Ivabradine reduced the 
combined endpoint of mortality 
and hospitalization  in patients 
with symptomatic HF and LV EF 
≤35%, in sinus rhythm and with a 
heart rate ≥70 beats per minute 
(bpm).  
eurheartj.oxfordjournals.org/content/early/2016/06/08/eurheartj.ehw128 drsvenkatesan.com/tag/ivabradine/ 
Treatment 
(Not Recommended) 
• Hydroxy-3-methylglutaryl-
coenzyme A reductase 
(‘statins’). 
• Oral anticoagulants and 
antiplatelet therapy. 
• Renin inhibitors. 
• Calcium-channel blockers. 
 
 
eurheartj.oxfordjournals.org/content/early/2016/06/08/eurheartj.ehw128 consumerreports.org/cro/2014/03/treating-high-cholesterol-with-statins/index.htm 
Treatment 
(Interventional Treatment) 
• Implantable cardioverter-
defibrillator. 
• Cardiac resynchronization 
therapy. 
• Revascularization procedures. 
• Valve replacement/repair. 
• Ventricular restoration. 
• Extracorporeal membrane 
oxygenation. 
• Ventricular assist devices. 
• Heart transplantation. 
• Total artificial heart. 
eurheartj.oxfordjournals.org/content/early/2016/06/08/eurheartj.ehw128 emedicine.medscape.com/article/163062-overview#a1 www.azheartrhythmcenter.com/procedures/ 
Treatment 
(Palliative Care) 
The growing number of 
patients with Stage IV HF 
(intractable symptoms of 
fatigue, shortness of breath 
or chest pain at rest despite 
optimal medical therapy) 
should be considered for 
palliative care or hospice, 
according to American 
College of 
Cardiology/American Heart 
Association guidelines. 
eurheartj.oxfordjournals.org/content/early/2016/06/08/eurheartj.ehw128 www.eapcnet.eu/Themes/Specificgroups/Heartdisease.aspx 
Prognosis  
• Prognosis in HF can be assessed in multiple ways including 
clinical prediction rules and cardiopulmonary exercise testing. 
• HF is associated with significantly reduced physical and 
mental health, resulting in a markedly decreased quality of 
life. 
• Although some people survive many years, progressive 
disease is associated with an overall annual mortality rate of 
10%. 
• Approximately 18 of every 1000 persons will experience an 
ischemic stroke during the first year after diagnosis of HF. 
•  As the duration of follow-up increases, the stroke rate rises to 
nearly 50 strokes per 1000 cases of HF by 5 years.[ 
en.wikipedia.org/wiki/Heart_failure#Prognosis 
Prophylaxis 
• A person's risk of developing HF is inversely related to their 
level of physical activity.  
• Those who achieved at least 500 MET-minutes/week (the 
recommended minimum by U.S. guidelines) had lower HF risk 
than individuals who did not report exercising during their 
free time; the reduction in heart failure risk was even greater 
in those who engaged in higher levels of physical activity than 
the recommended minimum. 
en.wikipedia.org/wiki/Heart_failure#Prevention 
Abbreviations  
• ACE - angiotensin converting enzyme  
• ACE-Is - angiotensin converting enzyme 
blockers  
• ACEP -American College of Emergency 
Physicians 
• ARBs - angiotensin receptor blockers  
• ARNI -angiotensin receptor neprilysin 
inhibitor 
• BMI  - body mass index  
• BNP – Brain (B-type) natriuretic peptide 
• Bpm - beats per minute  
• CAD - coronary artery disease 
• CKD – chronic kidney disease 
• ECG – electrocardiography 
• EF - ejection fraction  
• HFpEF – HF with preserved EF 
• HR - heart rate  
• HF – heart failure 
• PVL - pressure–volume loop  
• ICD - International Classification of 
Diseases  
• LV - left ventricle  
• LVH - LV hypertrophy 
• MI - myocardial infarction 
• NOS - Not Otherwise Specified  
• NT- proBNP - N-terminal pro-B type 
natriuretic peptide 
• PVL - pressure–volume loop 
• RAAS - renin-angiotensin-aldosterone 
system   
• RV - right ventricle 
• SV - stroke volume   
 
 
 
 
Diagnostic and treatment guidelines 
Europe 
• 2016 ESC Guidelines for the diagnosis and treatment of acute 
and chronic heart failure 
• Treatment of heart failure in adult congenital heart disease: a 
position paper of the Working Group of Grown-Up Congenital 
Heart Disease and the Heart Failure Association of the 
European Society of Cardiology 
North America 
•  2013 ACCF/AHA Guideline for the Management of Heart 
Failure 
 
 
 
